Skip to content
Wednesday, November 11, 2026
Summit Gamble Point

Users Stopping Slimming Jabs Gain Back Pounds Four Times Faster Than Those on Conventional Diets

Illustration of medical syringe and weighing machine
Obesity treatment often requires long-term strategies.

New research indicates that individuals who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy may regain shed pounds at a significantly accelerated pace than those who end conventional diet and exercise regimens.

Published data in a leading health publication demonstrates that while obese individuals can lose a large proportion of their body weight while on the medication, the mass returns at an average rate of 0.8 kg per month once they quit.

"Individuals buying such medications should be cognizant of the risk of quick rebound weight gain when the therapy ends," warns researcher Dr. Susan Jebb.

Such speed of recovery means a reversion to original weight in about 18 months.

Comparing Therapies

The research, which looked at dozens of trials involving over 9,000 of participants, compared the results of GLP-1 agonists with other pills.

Researchers point out that people who lose weight through diet and exercise generally see a slower creep back—around 100 grams monthly—post-intervention.

The Reason for the Rapid Regain

Doctors propose the mode of action of the injections explains the accelerated weight return.

These medications copy a body's own chemical called glucagon-like peptide-1, which moderates appetite.

"Long-term administration of the hormone levels far above than the body's typical production could lead to the system to produce less of its endogenous GLP-1, and may also diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics expert.

"Discontinuation of this GLP-1 'fix' means appetite is unsuppressed, making overeating a significant risk."

An Ongoing Disease?

Medical guidelines recommend the injections for people with weight-linked health risks, accompanied by prescribed lifestyle changes.

Many experts say that, due to the likelihood of relapse, the treatment might need to be life-long.

This view is supported by pharmaceutical companies, who note that the findings "underscore the chronic character of obesity," comparing it to managing conditions like diabetes.

Patient Accounts

People who have discontinued the jabs report a sudden return of appetite.

"It felt as if something activating and I was suddenly extremely hungry," recalled an individual.

The struggle is worsened if individuals have not established lasting dietary or behavioural modifications during treatment.

Widespread Use

Figures indicate that millions of people in the UK have tried weight-loss jabs in the past year, with desire being substantial.

  • Adoption is more common among females compared to men.
  • The 40s and 50s demographic shows the greatest level of interest.
  • A large proportion access the medications through private healthcare rather than the NHS.

Finally, clinicians emphasize that while GLP-1 drugs are effective tools for weight loss, they are not a permanent fix and lasting health benefits likely depends on combined behavioural management.

About the author

Adrienne Harris

Aria Vance is a professional gambling analyst with over a decade of experience in casino gaming and sports betting, specializing in strategy development and risk management.

Summit Gamble Point

Type to search articles.